Amgen’s Management Meeting Takeaways
<p>RBC Capital analysts provided their takeaways from Investor Call with the management of <a href='https://financialmodelingprep.com/financial-summary/AMGN'>Amgen Inc. (NASDAQ:AMGN)</a>, discussing product (and revenue) dynamics coming out of Q1/23, the latest on the Horizon Therapeutics deal, its closing, and what is ahead for integrating the new portfolio, pipeline highlights including the anticipated AMG133-led program efforts to differentiate within the obesity space, as well as the long-term outlook to layer diversified but intentioned growth off the company’s current commercial base. </p>
<p>While the analysts continue to find balance with the company’s story and shares, they believe the news flow remains worth watching as new sources of momentum through internal and external development emerge, though pending the Horizon Therapeutics deal close and integration as well as a glimpse at what is next to spark investor enthusiasm, they reiterate their Sector Perform rating and $254 price target on the company’s shares.</p>

NASDAQ:AMGN